Flow Cytometry

This is the latest episode of the free DDW podcast, “Revealing the magic of cell therapy”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “The magic of cell therapy” and “Cellular assays to bridge the gap in immunogenicity prediction”. In the first article, Marjie […]

This paid-for advertorial by Bio-Rad appeared in the DDW ebook – Innovating in the lab: an essential guide to drug discovery technology. In the following article Richard J Cuthbert, PhD, Global Commercialisation Product Manager, Flow and Antibodies, Bio-Rad Laboratories examines the rise of flow cytometry as a screening tool. In recent years, the use of flow cytometry in drug […]

Flow cytometry is a high throughput quantitative analysis tool that employs fluorescent-labelled molecules for multi-parametric analysis of millions of individual cells or particles. In biomedical sciences, the flow cytometry assays involve a careful selection of antibodies, fluorochrome labels for detection, and often requires optimisation of protocols for an accurate analysis of sample specific target antigens. […]

Flow cytometry is a powerful tool allowing you to detect, measure, and quantify single cells or particles in suspension as they pass through a laser. However, to produce impactful results, experiments must be designed with care. This guide takes you through the fundamentals of flow cytometry, provides useful practical advice to optimise your experiments and […]

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It took place on 14 Dec, 4PM GMT, 5PM CET.  Watch on Demand […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]

Major advances have been achieved in targeted immunotherapy with significant clinical benefits for patients. However, on-target/off-tumour toxicity is still a major concern, which highlights the clinical need for better targets to improve the safety profile of immunotherapies.   On-target/off-tumour toxicity is mainly based on the expression of tumour-associated antigens (TAA) in healthy tissues under physiological conditions. New approaches have […]

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is often tempered by antidrug antibodies (ADAs), which specifically recognise the therapeutic molecule as […]

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients.  Deriving Context from Immunological Data with Advanced Flow Cytometry will be presented by Nina Senutovitch Ph.D, Senior Scientist, Product […]

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells.  She presented this free webinar on 4 November […]